DOCSLIB.ORG

William Nichol Whiteley

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
William Nichol Whiteley Blood markers for the diagnosis and prognosis of stroke William Nichol Whiteley PhD by Research University of Edinburgh 2010 Whiteley W.N . Blood Markers in Stroke University of Edinburgh 2010 Table of contents Table of contents ................................................................................................................... 2 Table of tables........................................................................................................................ 7 Table of figures.................................................................................................................... 11 Abstract................................................................................................................................. 14 Declaration........................................................................................................................... 17 Publications and awards relating to the work of this thesis......................................... 18 Abbreviations ...................................................................................................................... 21 Acknowledgments and my contribution to the work of the thesis ............................. 24 Chapter 1. Introduction ............................................................................................... 26 The importance of diagnosis and prognosis ............................................................... 26 Aims of the thesis............................................................................................................ 26 Stroke and population health........................................................................................ 27 The definition of stroke .................................................................................................. 27 Stroke subtypes ............................................................................................................... 28 The clinical diagnosis of stroke ..................................................................................... 29 Difficulties of acute imaging.......................................................................................... 33 Potential advantages of blood markers for stroke diagnosis.................................... 35 Predicting outcome after stroke.................................................................................... 37 Blood markers in improving prediction of stroke outcome...................................... 39 2 Whiteley W.N . Blood Markers in Stroke University of Edinburgh 2010 Chapter 2. Blood markers in the diagnosis of ischaemic stroke: a systematic review ................................................................................................................. 40 Introduction ..................................................................................................................... 40 Methods............................................................................................................................ 41 Results............................................................................................................................... 43 Discussion ........................................................................................................................ 46 Tables................................................................................................................................ 52 Figures .............................................................................................................................. 60 Chapter 3. Validation of clinical scores for the diagnosis of stroke and transient ischaemic attack: BBISS, a prospective cohort study ..................................................... 63 Introduction ..................................................................................................................... 63 Methods............................................................................................................................ 64 Results............................................................................................................................... 78 Discussion ........................................................................................................................ 82 Tables................................................................................................................................ 87 Figures ............................................................................................................................ 102 Chapter 4. Blood markers of inflammation, thrombosis, thrombolysis, cardiac strain, neural and glial damage and the diagnosis of acute cerebrovascular diseases in an emergency department: BBISS, a prospective cohort study ............................. 107 Introduction ................................................................................................................... 107 Methods.......................................................................................................................... 109 Results............................................................................................................................. 121 Discussion ...................................................................................................................... 127 3 Whiteley W.N . Blood Markers in Stroke University of Edinburgh 2010 Chapter 5. Blood markers for the prognosis of ischaemic stroke: a systematic review 146 Introduction ................................................................................................................... 146 Methods.......................................................................................................................... 146 Results............................................................................................................................. 148 Discussion ...................................................................................................................... 150 Conclusions.................................................................................................................... 155 Tables.............................................................................................................................. 157 Figures ............................................................................................................................ 159 Chapter 6. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin 6................................................... 164 Introduction ................................................................................................................... 164 Methods.......................................................................................................................... 165 Results............................................................................................................................. 170 Discussion ...................................................................................................................... 173 Tables.............................................................................................................................. 178 Figures ............................................................................................................................ 184 Chapter 7. Plasma and serum markers of inflammation, thrombolysis, thrombosis, cardiac strain, neural and glial damage and poor outcome after acute cerebrovascular disease: BBISS, a prospective cohort study ...................................... 188 Introduction ................................................................................................................... 188 Methods.......................................................................................................................... 189 Results............................................................................................................................. 196 Discussion ...................................................................................................................... 201 4 Whiteley W.N . Blood Markers in Stroke University of Edinburgh 2010 Tables.............................................................................................................................. 207 Figures ............................................................................................................................ 225 Chapter 8. The association of circulating inflammatory markers with recurrent vascular events after stroke: ESS, a prospective cohort study.................................... 233 Introduction ................................................................................................................... 233 Methods.......................................................................................................................... 234 Results............................................................................................................................. 237 Discussion ...................................................................................................................... 241 Conclusion ..................................................................................................................... 244 Tables.............................................................................................................................
Load more

Recommended publications
  • Und Serumspiegel Von S-100B Und GFAP Nach Schädelhirntrauma: Aussagekraft in Der Akutdiagnostik Und Möglicher Prognostischer Wert
    Aus dem Institut für Neuroradiologie der Universität zu Lübeck Direktor: Prof. Dr. med. D. Petersen ______________________________________________________ Plasma- und Serumspiegel von S-100B und GFAP nach Schädelhirntrauma: Aussagekraft in der Akutdiagnostik und möglicher prognostischer Wert Inauguraldissertation zur Erlangung der Doktorwürde der Universität zu Lübeck - Aus der medizinischen Fakultät - vorgelegt von Elke Steinmeier aus Braunschweig Lübeck, 2006 Erster Berichterstatter Priv. Doz. Dr. med. Ulrich Missler Zweiter Berichterstatter/ Berichterstatterin Priv. Doz. Dr. med. Jan Gliemroth Tag der mündlichen Prüfung 03.05.2007 Zum Druck genehmigt Lübeck, den 03.05.07 gez. Prof. Dr. med. Werner Solbach Dekan der Medizinischen Fakultät 2 Inhalt Inhalt 3 1. Grundlagen 5 1.1 Einleitung und Fragestellung 5 1.2 Schädelhirntrauma 8 1.3 Zerebrale Strukturproteine 12 1.4 Das S-100 Protein 13 1.4.1 Vorkommen der S-100 Monomere 14 1.4.2 Funktion der S-100 Proteine 15 1.5 Das saure gliale Faserprotein (GFAP) 16 1.5.1 Vorkommen des GFAP im menschlichen Körper 16 1.5.2 Funktion des GFAP Proteins 16 2. Patienten, Material und Methoden 18 2.1 Auswahl von Patienten und Kontrollpersonen 18 2.2 Probengewinnung und Verarbeitung 18 2.3 Material 19 2.3.1 Antikörper 19 2.3.2 Chemikalien und verwendete Pufferlösungen 19 2.3.2.1 Herstellung der Enhancement-Lösung 19 2.3.2.2 Herstellung des Waschpuffers 20 2.3.2.3 Herstellung des TRIS/HCl/NaCl-Puffers 20 2.4 Immunfluoreszenzassay zur Bestimmung des S-100B Proteins 20 2.5 Immunfluoreszenzassay zur Bestimmung des GFAP Proteins 22 2.6 Neurologische Beurteilungsskalen 23 2.6.1 Glasgow Coma Skala 23 2.6.2 Glasgow Outcome Skala 25 2.6.3 CCT-Skala 25 2.7 Statistische Methoden 26 3.
    [Show full text]
  • Indication Phase Route Country Name Role Country Type
    Alzheimer's Disease (Preclinical & Research) Drug Development Phase Organisations Drug Introduction Synonyms Mechanism Of Action Indication Phase Route Country Name Role Country Type Ownership IRX 4204 IRX 4204 is an orally bioavailable, first in class, AGN 194204 Retinoid X receptor agonists Prostate cancer Phase II PO USA Allergan Originator USA Large Pharma, Pharmaceutical Public retinoid X receptor (RXR; rexinoid) agonist being AGN-194204 Alzheimer's disease Preclinical PO USA Io Therapeutics Owner World Biopharmaceutical Private developed by Io Therapeutics. The initial focus is AGN194204 Parkinson's disease Preclinical PO USA Mount Sinai School of Medicine Collaborator USA University N/A for the treatment of castration-resistant prostate ALRT 4204 The Michael J. Fox Foundation for Parkinsons Research Collaborator USA Institution N/A cancer, but may also be developed for non-small cell lung cancer. IRX 4204 demonstrated activity ALRT-4204 against a variety of human cancers in vitro and ALRT4204 in animal models, including prostate, breast, IRX-4204 1 pancreatic, and lung [CONT.] IRX4204 NRX 194204 NRX 4204 NRX-194204 NRX-4204 NRX194204 NRX4204 VTP 194204 VTP-194204 VTP194204 Stem cell therapies - RNL BIO RNL BIO (South Korea) is researching and Adipose stem cell therapies - RNL BIO Cell replacements Facial hemiatrophy Phase II Parenteral South Korea Asan Medical Center Collaborator South Korea Hospital N/A developing stem cell therapies derived from adult Adult-derived stem cell therapies - RNL BIO Osteoarthritis Phase II Intra articular South Korea RNL BIO Originator South Korea Biotechnology sources, such as cord blood, placenta, hair Astrostem Thromboangiitis obliterans Phase II Parenteral South Korea RNL BIO Owner South Korea Biotechnology follicle and adipose (fat) tissue.
    [Show full text]
  • Biomarkers for Ischaemic Stroke
    BIOMARKERS FOR ISCHAEMIC STROKE NAZEEHA HASAN A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY SUPERVISORS: DR PANKAJ SHARMA DR ROBERT EDWARDS DEPARTMENT OF MEDICINE IMPERIAL COLLEGE LONDON DECEMBER 2013 ABSTRACT Background: Current diagnostic, prognostic and risk stratification tools are inadequate for effective ischaemic stroke management. Hypothesising that –omics approaches can be used to detect novel candidate biomarkers for ischaemic stroke, this thesis aimed to evaluate the current status of biomarkers for ischaemic stroke and develop strategies for biomarker discovery. Methods: Systematic literature review and individual patient data meta-analyses were performed to assess current candidate biomarkers associated with ischaemic stroke. Proteomic SELDI-TOF MS profiling was undertaken to identify novel blood-based protein biomarkers for the diagnosis of acute ischaemic stroke, consisting of a pilot study and a subsequent well- powered discovery study of 104 patients. In an integrative genomics study, transcriptomics data from carotid endarterectomy samples was combined with a genome-wide association study meta-analysis and subjected to functional enrichment analysis to detect differential gene expression or alternative splicing profiles that may be under the control of a genetic variant. Results: Systematic review and meta-analysis concluded that no current candidate biomarkers could be recommended for routine clinical practice, supporting the pursuit of novel biomarkers for ischaemic stroke and informing the design of subsequent experimental studies. SELDI-TOF MS detected two plasma protein ions, m/z 3699 and m/z 6640, which could differentiate between acute cerebral ischaemia and stroke mimics. Protein ion m/z 6640, identified as ApoC-1, highlighted the role of lipid dysregulation and was postulated to be a novel candidate biomarker for acute cerebral ischaemia.
    [Show full text]
  • Mesh Terms for 2002
    Mesh Terms for Fiscal Year 2002 1,2-DIMETHYLHYDRAZINE 1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE 1,4-ALPHA-GLUCAN BRANCHING ENZYME 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE 1-ACYLGLYCEROPHOSPHOCHOLINE O-ACYLTRANSFERASE 1-BUTANOL 1-CARBOXYGLUTAMIC ACID 1-DEOXYNOJIRIMYCIN 1-METHYL-3-ISOBUTYLXANTHINE 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE 1-METHYL-4-PHENYLPYRIDINIUM 1-NAPHTHYLAMINE 1-NAPHTHYLISOTHIOCYANATE 1-OCTANOL 1-PHOSPHATIDYLINOSITOL 3-KINASE 1-PHOSPHATIDYLINOSITOL 4-KINASE 1-PROPANOL 1-SARCOSINE-8-ISOLEUCINE ANGIOTENSIN II 11-HYDROXYCORTICOSTEROIDS 12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID 15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOI 15-OXOPROSTAGLANDIN 13-REDUCTASE 16,16-DIMETHYLPROSTAGLANDIN E2 17 ALPHA-HYDROXYPROGESTERONE ALDOLASE 17-HYDROXYCORTICOSTEROIDS 17-HYDROXYPROGESTERONE 17-HYDROXYSTEROID DEHYDROGENASES 17-KETOSTEROIDS 18-HYDROXYCORTICOSTERONE 18-HYDROXYDESOXYCORTICOSTERONE 19-IODOCHOLESTEROL 2',3'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES 2',5'-OLIGOADENYLATE SYNTHETASE 2,2'-DIPYRIDYL 2,3-DIKETOGULONIC ACID 2,3-DIPHOSPHOGLYCERATE 2,4,5-TRICHLOROPHENOXYACETIC ACID 2,4-DICHLOROPHENOXYACETIC ACID 2,4-DINITROPHENOL 2,5-DIMETHOXY-4-METHYLAMPHETAMINE 2,6-DICHLOROINDOPHENOL 2-ACETOLACTATE MUTASE 2-ACETYLAMINOFLUORENE 2-AMINO-5-PHOSPHONOVALERATE 2-AMINOADIPIC ACID 2-AMINOPURINE 2-CHLOROADENOSINE 2-DEHYDRO-3-DEOXYPHOSPHOHEPTONATE ALDOLASE 2-HYDROXY-5-NITROBENZYL BROMIDE 2-HYDROXYPHENETHYLAMINE 2-ISOPROPYLMALATE SYNTHASE 2-METHYL-4-CHLOROPHENOXYACETIC ACID 2-NAPHTHYLAMINE 2-PROPANOL 20-HYDROXYSTEROID DEHYDROGENASES
    [Show full text]
  • Insights from the Sequence Similarity of Zika Virus Proteins with the Human Nerve Proteins
    Open access www.bioinformation.net Hypothesis Volume 14(5) Insights from the sequence similarity of Zika virus proteins with the Human nerve proteins Prasanna Marsakatla1, Sujai Suneetha1, Joshua Lee2, Paari Dominic Swaminathan3, Logeshwaran Vasudevan4, Rachael Supriya1, Lavanya Moses Suneetha1* Received April 10, 2018; Revised April 23, 2018; Accepted April 30, 2018; Published May 31, 2018 1CODEWEL Nireekshana ACET, Narayanaguda, Hyderabad -500029, Telangana, India; 2York University, Department of Science, 4700 Keele St, Toronto, ON M3J 1P3, Canada; 3LSU Health Sciences Center, Center for Cardiovascular Diseases and Sciences Shreveport, LA, USA; 4Presidency College, Department of Zoology, Chennai-05, India; Lavanya Moses Suneetha – E:mail - [email protected]; Phone: +91-40-23221033; +91-9885150381; *Corresponding Author doi:10.6026/97320630014194 Abstract: Massive peptide sharing between the Zika virus polyprotein and host tissue proteins could elicit significant host-pathogen interactions and cross-reactions leading to autoimmune diseases. This study found similarities in the Zika V proteins and human nerve tissue proteins. 63 human nerve proteins were screened for similarities with the Zika V of which Neuromodulin, Nestin, Galanin, Bombesin, Calcium-binding protein were found to have similarities to the Zika V poly protein C at different sequence regions. These sequence similarities could be significant in regulating pathogenic interactions/autoimmunity, as Polyprotein C is known to be a virulent factor. Keywords: Zika V, Nerve tissue proteins, Neuropathogenesis, Bioinformatics, BLAST, Neuromodulin, Nestin, Bombesin, Galanin, Calcium-binding protein. Background: Tyro3, and TIM-1) facilitating the entry of the Zika V into The Zika Virus (Zika V), is an emerging infectious disease agent different tissue cells [7]. Cell culture experiments of the Zika V causing human birth defects.
    [Show full text]
  • Intiharin Biyokimyasal Belirteçleri Olarak Beyin Omurilik Sivisinda S100b Proteini Ve Serotonin Düzeylerinin Değerlendirilmesi
    T.C. SELÇUK ÜNİVERSİTESİ SAĞLIK BİLİMLERİ ENSTİTÜSÜ İNTİHARIN BİYOKİMYASAL BELİRTEÇLERİ OLARAK BEYİN OMURİLİK SIVISINDA S100B PROTEİNİ VE SEROTONİN DÜZEYLERİNİN DEĞERLENDİRİLMESİ Kamil Hakan DOĞAN DOKTORA TEZİ BİYOKİMYA (TIP) ANABİLİM DALI DANIŞMAN Prof. Dr. Mustafa ÜNALDI KONYA - 2012 T.C. SELÇUK ÜNİVERSİTESİ SAĞLIK BİLİMLERİ ENSTİTÜSÜ İNTİHARIN BİYOKİMYASAL BELİRTEÇLERİ OLARAK BEYİN OMURİLİK SIVISINDA S100B PROTEİNİ VE SEROTONİN DÜZEYLERİNİN DEĞERLENDİRİLMESİ Kamil Hakan DOĞAN DOKTORA TEZİ BİYOKİMYA (TIP) ANABİLİM DALI DANIŞMAN Prof. Dr. Mustafa ÜNALDI Bu araştırma Selçuk Üniversitesi Bilimsel Araştırma Projeleri Koordinatörlüğü tarafından 11102026 proje numarası ile desteklenmiştir. KONYA - 2012 ÖNSÖZ Adli Tıp Uzmanı olarak Biyokimya Anabilim Dalı’nda doktora eğitimine, Biyokimya biliminin Adli Tıp alanında pek çok yerde kullanılması ve Adli Tıp’ın gelişmesinde çok önemli bir yeri olması nedeniyle başladım. Eğitimim boyunca da, Biyokimya’nın derinliklerine indikçe, aslında rutinde Adli Tıp alanında kullandığımız pek çok bilginin tamamen biyokimyasal süreçlere ve temellere dayandığı ve bu alanda ilerlemenin ancak iyi bir biyokimya bilgisine ve nosyonuna sahip olmakla gerçekleştirilebileceğini daha iyi kavradım. Bu zorlu süreçte doktora eğitimim boyunca bilgi ve deneyimleri ile bana yol gösteren başta tez danışmanım kıymetli hocam Prof.Dr. Mustafa Ünaldı’ya, İlgisini ve desteğini sürekli hissettiğim Biyokimya Anabilim Dalı Başkanı kıymetli hocam Prof.Dr. İdris Mehmetoğlu’na, Eğitimime katkı sağlayan Biyokimya Anabilim Dalı’nın tüm değerli öğretim üyelerine ve laboratuvar personeline, Doktora çalışmasına başlamamda motivasyonumu sağlayan ve tez çalışmam boyunca örneklerin toplanmasına bizzat katkı sağlayan kıymetli hocam Doç.Dr.Şerafettin Demirci’ye, Örneklerin analizi aşamasında samimi desteğini gördüğüm Arş.Gör.Dr. Erkan Taşyürek’e, Bu çalışmanın yapılabilmesi için gerekli maddi desteği 11102026 nolu projeyle sağlayan Selçuk Üniversitesi Bilimsel Araştırma Projeleri Koordinatörlüğü’ne, Her zaman desteğini gördüğüm eşim Yrd.Doç.Dr.
    [Show full text]
  • Early Stage & Preclinical MOA Counts Early Stage & Preclinical Company
    Early Stage & Preclinical MOA counts Early Stage & Preclinical Company Activity MOA # of profiles Company # of profiles Aβ inhibitors 58 Merck & Co 12 Undefined 33 AstraZeneca 11 Immunostimulants 19 Pfizer 10 BACE1 protein inhibitors 18 Bristol-Myers Squibb 6 Tau protein inhibitors 13 Roche 6 APP secretase inhibitors 12 Wyeth 6 AChe inhibitors 8 GlaxoSmithKline 5 Alpha-synuclein inhibitors 7 Takeda 5 APP secretase modulators 7 University of California at Irvine 5 5-HT6 antagonists 7 Abbott Laboratories 4 Tau protein modulators 6 AbbVie 4 Amyloid beta-protein precursor inhibitors 5 Astellas Pharma 4 Antioxidants 5 Bayer HealthCare Pharmaceuticals 4 Cell replacements 5 Biogen Idec 4 Immunomodulators 5 Daewoong Pharmaceutical 4 NMDA receptor antagonists 5 Eli Lilly 4 Positron-emission tomography enhancers 5 Northwestern University 4 Alpha7 nicotinic acetylcholine receptor agonists 4 Suven Life Sciences 4 Amyloid inhibitors 4 Alzheimers Drug Discovery Foundation 3 Chelating agents 4 Boehringer Ingelheim 3 Nerve growth factor stimulants 4 CHDI 3 Neuron stimulants 4 ChemDiv 3 Serotonin 4 receptor agonists 4 Elan Corporation 3 Amyloid beta-protein modulators 3 EnVivo Pharmaceuticals 3 Calcium channel antagonists 3 JANSSEN Alzheimer Immunotherapy 3 Cathepsin S inhibitors 3 Johnson & Johnson Pharmaceutical Research & Development 3 G protein-coupled receptor modulators 3 Lay Line Genomics 3 Muscarinic M1 receptor agonists 3 Ligand Pharmaceuticals 3 Nicotinic receptor agonists 3 McGill University 3 Advanced glycosylation end-product receptor antagonists
    [Show full text]